相关实验视频

Updated: May 17, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

超微小的纳米颗粒减轻陶过酸化以恢复突触完整性和促进阿尔茨海默病的认知功能

Hanbing Xu^1,2,3, Gang Wang^1,3, Zhilin Jiang²

¹Department of Anesthesiology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, China.

Advanced healthcare materials

|May 16, 2025

概括

功能化纳米粒子抑制USP14以减少阿尔茨海默病 (AD) 中的Tau积累. 这种方法通过恢复小鼠的大脑功能和突触完整性来缓解AD症状.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
纳米医学是一种纳米医学.

背景情况:

阿尔茨海默氏病 (AD) 的特征是Tau过酸化,这是一个关键的病理标志.
乌比基特异性蛋白酶14 (USP14) 活性会损害蛋白质体功能,加速tau的积累.
抑制USP14呈现出AD治疗的潜在治疗策略.

研究的目的:

为了研究 wogonoside 功能化的超小 Cu2-xSe 纳米颗粒 (CSPW NPs) 在缓解 Tau 过酸化和 AD 症状方面的治疗潜力.
阐明涉及USP14抑制和无素-蛋白酶体通路的作用机制.
评估细胞膜涂层纳米颗粒 (CSPW@CM NPs) 对血脑屏障透和神经元向的有效性.

主要方法:

合成和表征的功能化的超小Cu2-xSe纳米粒子 (CSPWNP).
在体外和体内评估CSPWNP对Tau高酸化和USP14活性的影响.
在AD小鼠模型中,评估CSPW@CMNP的血脑屏障穿越能力,使用聚焦超声波辅助.
在接受治疗的AD小鼠中分析神经元功能,突触完整性和认知性能.

主要成果:

通过抑制USP14和激活无素-蛋白酶体通路,CSPW NPs显著降低了高酸化Tau的积累.
CSPW@CM NPs成功穿越了血脑屏障,并在大脑中积累,准神经元.
用CSPW@CMNP治疗增强了微管稳定性,减轻了突触损失,恢复了突触完整性,并缓解了AD小鼠的认知缺陷.

结论:

功能化的纳米粒子代表了阿尔茨海默病的有希望的治疗策略,通过准USP14.
抑制USP14有效地降低了Tau过酸化,并改善了AD相关的神经病理和认知衰退.
基于纳米粒子的药物输送系统显示出克服血脑屏障和治疗AD和陶病等神经退行性疾病的潜力.

关键词:

阿尔茨海默氏症的疾病是阿尔茨海默氏症.塔乌·塔乌 (Tau Tau) 是一个美国P14纳米抑制剂过酸化过酸化的方法突触突触是指突触中的突触.

更多相关视频

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.